Article Text

Download PDFPDF
The GDF5 rs143383 polymorphism is associated with osteoarthritis of the knee with genome-wide statistical significance
  1. Ana M Valdes1,
  2. Evangelos Evangelou2,
  3. Hanneke J M Kerkhof3,4,
  4. Agu Tamm5,
  5. Sally A Doherty6,
  6. Kalle Kisand5,7,
  7. Ann Tamm8,
  8. Irina Kerna5,
  9. Andre Uitterlinden3,4,
  10. Albert Hofman8,
  11. Fernando Rivadeneira3,4,
  12. Cyrus Cooper10,11,
  13. Elaine M Dennison10,
  14. Weiya Zhang6,
  15. Kenneth R Muir12,
  16. John P A Ioannidis2,
  17. Margaret Wheeler6,
  18. Rose A Maciewicz13,
  19. Joyce B van Meurs3,4,
  20. Nigel K Arden10,11,
  21. Tim D Spector1,
  22. Michael Doherty6
  1. 1Department of Twin Research and Genetic Epidemiology Unit, St Thomas' Hospital, King's College London, London, UK
  2. 2Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
  3. 3Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
  4. 4Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA), Leiden, The Netherlands
  5. 5Department of Internal Medicine, University of Tartu, Tartu, Estonia
  6. 6Academic Rheumatology, University of Nottingham, City Hospital Nottingham, Nottingham, UK
  7. 7Immunology Group, Institute of General and Molecular Pathology, University of Tartu, Tartu, Estonia
  8. 8Department of Sports Medicine and Rehabilitation, University of Tartu, Tartu, Estonia
  9. 9Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
  10. 10MRC Epidemiology Resource Centre, Southampton, UK
  11. 11Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK
  12. 12Health Sciences Research Institute, Warwick Medical School, University of Warwick, Warwick, UK
  13. 13Respiratory and Inflammation Research Area, AstraZeneca, Charnwood R&D, Loughborough, UK
  1. Correspondence to Dr Ana M Valdes, Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas Hospital, London SE1 7EH, UK; ana.valdes{at}kcl.ac.uk

Statistics from Altmetric.com

Osteoarthritis of the knee is a major cause of pain, disability and the use of healthcare resources among middle-aged and older people.1 Although osteoarthritis is multifactorial, it is known to have a significant genetic contribution and a number of studies have attempted to dissect such a contribution (see Valdes and Spector2 for review).

The GDF5 gene encodes the growth differentiation factor 5, a bone morphogenetic protein involved in joint formation, expressed in different joint structures, which has been shown to ameliorate tendon, ligament and bone healing after trauma in mice.3 4

A promoter polymorphism (rs143383) in GDF5 has been found to be strongly associated with both hip and knee osteoarthritis in Asian individuals,4 and is the most widely replicated genetic association with knee osteoarthritis, although much less so for hip and hand osteoarthritis.5 This variant is functional, with the lower gene expression variant having increased genetic risk.4

A large-scale meta-analysis reported the association of the major (T) allele with knee osteoarthritis achieved OR 1.15 p=9.7×10−7 and achieved p=9×10−5 (OR 1.13, 95% CI 1.06 to 1.20) when Asian subjects were excluded.5

The genome-wide statistical significance level of p<5×10−8 is increasingly …

View Full Text

Footnotes

  • Funding This work was supported by EC framework 7 programme grant 200800 TREAT-osteoarthritis, Arthritis Research UK (ARUK), the Medical Research Council (UK), the Oxford NIHR Musculoskeletal Biomedical Research Unit, the Estonian Science Foundation grant no 5308, the Estonian Ministry of Social Affairs grants no 9.6-4/2035 and 12.1-5/597 and by AstraZeneca, Macclesfield, UK. The generation and management of genome-wide association genotype data for the Rotterdam Study is supported by The Netherlands Organisation of Scientific Research NWO Investments (no 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014–93-015; RIDE2) and The Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) (project no 050-060–810).

  • Competing interests RM is an Astra Zeneca plc employee and owns Astra Zeneca stock. All other authors declare no competing interests.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the the Nottingham case–control and the GOAL study protocols were approved by the Nottingham City Hospital and North Nottinghamshire ethical committees. The Hertfordshire Cohort Study was approved by the East and North Hertfordshire ethical committees. The medical ethics committee of Erasmus University Medical School approved the Rotterdam study III. The Ethics Committee of the University of Tartu approved the Estonian knee osteoarthritis study.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.